title: Comparison of three patterns of feed supplementation with live Saccharomyces cerevisiae yeast on postweaning diarrhea, health status, and blood metabolic profile of susceptible weaning pigs orally challenged with Escherichia coli F4ac.
abstract: The development of effective feeding strategies to reduce the detrimental effect of enterotoxigenic F4ac (ETEC) plays a crucial role in reducing the occurrence of therapeutic intervention with antibiotics in livestock. The ability of CNCM I-4407 (SCC), supplied in different patterns to counteract ETEC infection in weaned pigs, was evaluated. Fifty pigs weaned at 24 d were then divided into 5 groups: control (CO), CO + colistin (AB), CO + 5 × 10(10) cfu of SCC/ kg feed, from d 0 to 21 (PR), CO + 5 × 10(10) cfu of SCC/ kg feed from d 7 to 11 (CM), and CO + 1 shot of 2 × 10(11) cfu of SCC when the first diarrhea appeared (CU). On d 7 postweaning, all the pigs were orally challenged with 10(8) cfu of ETEC. Blood samples were taken from the pigs (d 7, 8, 12, and 21) while the fecal excretion of ETEC was assessed on d 7 and 10. Fecal consistency was scored from 12 h before infection to 144 h postinfection (p.i.). On d 21, the pigs were sacrificed. The in vitro adhesion test on the intestinal villi confirmed individual susceptibility to ETEC, excluding the presence of resistant pigs. Growth performance did not differ between the treatments. Mortality was reduced in the AB group (P< 0.01) and, marginally, in the PR group (P = 0.089) when compared to the CO group. The CO group had a higher fecal score than AB in the period of observation (from P = 0.01 to P< 0.001). Yeast administration reduced the fecal score when compared to the CO group 12 and 48 h p.i. (P = 0.04). Total IgA never differed among the treatments, but the ETEC-specific IgA concentration was lower in the AB group than in CO (P = 0.04) at d 12. Four days p.i., the pigs fed live yeast had reduced ETEC excretion compared with the CO pigs (P = 0.05). Blood concentrations of dodecenoyl-L-carnitine (P < 0.01), glutaryl-L-carnitine/hydroxyhex¬anoyl-L-carnitine, phosphatidylcholine diacyl and phosphatidylcholine diacyl (P = 0.01 and P< 0.01, respectively), and α-amino adipic acid (P < 0.01) were reduced in the AB group compared to the CO group; PR + CM reduced the concentration of sphingomyelin-ceramide (P = 0.02) and increased the concentration of decadienyl-L-carnitine (C10:2; P= 0.02) vs. CO. The CM group had an increased concentration of C10:2 (P < 0.01) compared to the PR group. In conclusion, the administration of live yeast, even in concomitance with ETEC infections, reduces pig illness and mortality. The strain of SCC tested did not show a therapeutic effect.
authors.forename: P
authors.initials: P
authors.lastname: Trevisi
authors.forename: M
authors.initials: M
authors.lastname: Colombo
authors.forename: D
authors.initials: D
authors.lastname: Priori
authors.forename: L
authors.initials: L
authors.lastname: Fontanesi
authors.forename: G
authors.initials: G
authors.lastname: Galimberti
authors.forename: G
authors.initials: G
authors.lastname: Calò
authors.forename: V
authors.initials: V
authors.lastname: Motta
authors.forename: R
authors.initials: R
authors.lastname: Latorre
authors.forename: F
authors.initials: F
authors.lastname: Fanelli
authors.forename: M
authors.initials: M
authors.lastname: Mezzullo
authors.forename: U
authors.initials: U
authors.lastname: Pagotto
authors.forename: Y
authors.initials: Y
authors.lastname: Gherpelli
authors.forename: R
authors.initials: R
authors.lastname: D'Inca
authors.forename: P
authors.initials: P
authors.lastname: Bosi
mesh_terms: D000821:Animal Feed / Q000032:analysis; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003967:Diarrhea / Q000382:microbiology / Q000517:prevention & control / Q000662:veterinary*; D004032:Diet / Q000662:veterinary; D019587:Dietary Supplements; D004926:Escherichia coli / Q000472:pathogenicity*; D004927:Escherichia coli Infections / Q000150:complications / Q000517:prevention & control / Q000662:veterinary; D005243:Feces; D006304:Health Status; D055442:Metabolome / Q000187:drug effects; D012441:Saccharomyces cerevisiae / Q000502:physiology; D013552:Swine / Q000097:blood / Q000382:microbiology*; D013553:Swine Diseases / Q000382:microbiology / Q000517:prevention & control*; D014886:Weaning; D015002:Yeast, Dried / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents